tion. Now, 5 months after stem cell transplantation, the patient is in complete remission and in good physical performance.
Reply to 'Rituximab activity in CD20-positive multiple myeloma' Leukemia (2008) We agree with Bergua et al.
1 on the possible superior efficacy of combination therapy treatment with rituximab and chemotherapy in CD20-positive multiple myeloma, with respect to rituximab alone, due to its synergism with many cytotoxic drugs. Nevertheless, the intention of our case report 2 was to highlight a possible role of subsequent immunotherapy after debulking with chemotherapy to reduce the residual disease. Of note, a strict follow-up in our patient showed the disease recurrence (10% of bone marrow monoclonal plasma cells) again, 6 months after rituximab interruption. We believe that optimal timing of anti-CD20 treatment in this subset of myeloma patients has still to be determined with a possible role for maintenance therapy. 
